Modern Biosciences to invest in vascular disrupting agent

Wednesday 9 July 2008

The UK drug development company, Modern Biosciences, has entered into an exclusive agreement with the University of Bradford, also of the UK, to develop a vascular disrupting agent for cancer. Financial terms were not disclosed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom